Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Orencia

Study type: Observational

Funder types: Industry

Identifiers

NCT02600455

IM101-515

Details and patient eligibility

About

The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.

Enrollment: 505 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients who are beginning to receive the treatment with ORENCIA Subcutaneous Injection 125mg Syringe 1mL under the approved indications, dosage, and administration

Trial design

505 participants in 1 patient group

Patients who are treated with ORENCIA

Description:

Patients who are treated with ORENCIA according to the approved indications, and dosage and administration

Treatment:

Drug: Orencia